Previous 10 | Next 10 |
Evolus, Inc. (EOLS) Q1 2021 Results Conference Call May 12, 2021 04:30 PM ET Company Participants Carol Ruth - The Ruth Group David Moatazedi - President and Chief Executive Officer Lauren Silvernail - Chief Financial Officer and EVP, Corporate Development Rui Avelar - Chief Medical Officer a...
Evolus (EOLS): Q1 GAAP EPS of $0.16 beats by $0.57.Revenue of $12.24M (+16.6% Y/Y) beats by $1.13M.Restructured the company balance sheet through the elimination of $127.4 million in debt and future milestone payments.Press Release For further details see: Evolus EPS beats by $0.57, bea...
Q1 2021 Net Revenues of $12.2 million, Despite Half-Quarter ITC Impact Full Resolution of International Trade Commission (ITC) Case Restructured Balance Sheet with March 31, 2021 Pro Forma Cash Position of $140 million 1 On Track for a $100 mill...
NEWPORT BEACH, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced two newly published peer review studies in Aesthetic Surgery Journal that ...
NEWPORT BEACH, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its first quarter 2021 financial results and provide a bus...
NEWPORT BEACH, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 7th Annual Truist Securit...
Cosmetic drug specialist Evolus (NASDAQ: EOLS) produced investor frowns on Thursday following its announcement of a dilutive secondary share issue. The stock closed down by 18.9%, recovering only slightly in after-hours trading. Evolus is floating 9 million shares of its common ...
Gainers: Takung Art (TKAT) +33%.Teradata (TDC) +29%.Renalytix AI (RNLX) +24%.Qualtrics International (XM) +24%.Galectin Therapeutics (GALT) +23%.Kaleido Biosciences (KLDO) +21%.CEL-SCI (CVM) +21%.Novan (NOVN) +20%.Nikola (NKLA) +17%.Equifax (EFX) +17%.Losers: Evolus (EOLS) ...
Evolus (EOLS) -19% after prices equity offering at $9.50.NeuBase Therapeutics (NBSE) -15% on launching stock offeringFisker (FSR) -10% after Goldman Sachs turns bearishCredit Suisse Group (CS) -5% on Q1 earnings release For further details see: Cr...
Evolus (EOLS) has priced its public offering of 9M common shares at $9.50/share, for expected gross proceeds of $85.5M.Underwriters' over-allotment is an additional 1.35M shares.Net proceeds will be used to fund the U.S. growth of Jeuveau, European pre-launch activities and general corpo...
News, Short Squeeze, Breakout and More Instantly...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will host an Investor Day on Thursday, September 12, 2024 in New York City. Attendees can join in-person or participate via webcast. The even...
Launching into this growth market 1 as part of the company’s geographic expansion strategy Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals Evolus, Inc. (NASDAQ: EOLS), a perf...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sandra Beaver, CFO, will present at the following investor conference. Event: The Canaccord Genuity 44 th Annual Growth Conference Date: T...